ZNF445: a homozygous truncating variant in a patient with Temple syndrome and multilocus imprinting disturbance

Masayo Kagami1*, Kaori Hara-Isono1, Keiko Matsubara1, Kazuhiko Nakabayashi2, Satoshi Narumi1, Maki Fukami1, Yumiko Ohkubo3, Hirotomo Saitsu4, Shuji Takada5 and Tsutomu Ogata1,3,4,6,7*

Abstract

Background: ZNF445, as well as ZFP57, is involved in the postfertilization methylation maintenance of multiple imprinting-associated differentially methylated regions (iDMRs). Thus, ZNF445 pathogenic variants are predicted to cause multilocus imprinting disturbances (MLIDs), as do ZFP57 pathogenic variants. In particular, the MEG3/DLK1:IG-DMR would be affected, because the postzygotic methylation imprints of the MEG3/DLK1:IG-DMR is maintained primarily by ZNF445, whereas that of most iDMRs is preserved by both ZFP57 and ZNF445 or primarily by ZFP57.

Results: We searched for a ZNF445 variant(s) in six patients with various imprinting disorders (IDs) caused by epimutations and MLIDs revealed by pyrosequencing for nine iDMRs, without a selection for the original IDs. Re-analysis of the previously obtained whole exome sequencing data identified a homozygous ZNF445 variant (NM_181489.6:c.2803C>T:p.(Gln935*)) producing a truncated protein missing two of 14 zinc finger domains in a patient with Temple syndrome and MLID. In this patient, array-based genomewide methylation analysis revealed severe hypomethylation of most CpGs at the MEG3:TSS-DMR, moderate hypomethylation of roughly two-thirds of CpGs at the H19/IGF2:IG-DMR, and mild-to-moderate hypomethylation of a few CpGs at the DIRAS3:TSS-DMR, MEST:alt-TSS-DMR, IGF2:Ex9-DMR, IGF2:alt-TSS, and GNAS-AS1:TSS-DMR. Furthermore, bisulfite sequencing analysis for the MEG3/DLK1:IG-DMR delineated a markedly hypomethylated segment (CG-A). The heterozygous parents were clinically normal and had virtually no aberrant methylation pattern.

Conclusions: We identified a ZNF445 pathogenic variant for the first time. Since ZNF445 binds to the MEG3/DLK1:IG-DMR and other iDMRs affected in this patient, the development of Temple syndrome and MLID would primarily be explained by the ZNF445 variant. Furthermore, CG-A may be the target site for ZNF445 within the MEG3/DLK1:IG-DMR.

Keywords: ZNF445, Postzygotic genomic imprint, Multilocus imprinting disturbance, Temple syndrome, MEG3/DLK1:IG-DMR

Background

Recent studies have identified multilocus imprinting disturbances (MLIDs) in a subset of patients with imprinting disorders (IDs) caused by epimutations affecting imprinting-associated differentially methylated regions (iDMRs) [1]. Although underlying factor(s) for MLIDs remains largely unknown, MLID-related genetic variants have been identified in several genes involved in the establishment of genomic imprints in the oocyte (e.g., NLRP7) [2].
and in the maintenance of postzygotic genomic imprints (e.g., ZFP57 [3]).

Recently, Takahashi et al. have reported that ZNF445, as well as ZFP57, plays a critical role in the maintenance of postfertilization methylation imprints [4]. ZNF445 consists of eight exons and encodes a 1,031 amino acid protein. ZNF445 belongs to the KRAB-containing KZFP family and carries a SCAN domain and 14 zinc finger (ZF) domains together with the KRAB domain (Fig. 1a). ZNF445 binds to multiple imprinting control regions (ICRs) within iDMRs and maintains methylation imprints by recruiting KRAB-associated protein 1 (KAP1) (alias, TRIM28) [4]. Thus, ZNF445 has a biological function similar to that of ZFP57, which also belongs to the KZFP family [4, 5]. It is predicted, therefore, that ZNF445 pathogenic variants lead to MLIDs, as do ZFP57 pathogenic variants [3]. In particular, the MEG3/DLK1:IG-DMR would be affected, because (1) chromatin immunoprecipitation (ChIP) analyses using human embryonic stem (hES) cells or human embryonic kidney 293 T (HEK293T) cells have shown that the MEG3/DLK1:IG-DMR is associated primarily with ZNF445 binding, while most iDMRs are associated with both ZFP57 and ZNF445 bindings or primarily with ZFP57 binding [4, 5]; and (2) the MEG3/DLK1:IG-DMR is hypomethylated in ZNF445 knockout hES cells [4].

Here we report the first ZNF445 pathogenic variant identified in a patient with Temple syndrome (TS14) and MLID.

Results

Patients

We examined six patients with IDs caused by epimutations, i.e., patient 1 with TS14, patient 2 with both Beckwith–Wiedemann syndrome (BWS) and pseudohypoparathyroidism type Ib (PHP-Ib), patients 3 and 5 with Silver–Russell syndrome (SRS), and patients 4 and 6 with BWS, who were found to have MLIDs by pyrosequencing analysis for nine IDs-related iDMRs (Additional file 1: Table S1). Patients 1 and 2 have been reported previously [6, 7]. Uniparental disomies and deletions/duplications involving the IDs-related iDMRs were excluded by microsatellite analysis and custom-build oligo-microarray analysis for iDMRs, respectively. Here, since it was uncertain whether ZNF445 pathogenic variants could be identified in epimutations- and MLID-positive patients with TS14 or in those with other IDs, we studied all the six patients in whom whole exome sequencing (WES) has already been performed (patients 1 and 2 and their parents) [6, 7] or DNA samples and informed consent for WES have been obtained (patients 3–6 and the parents of patients 3–5; the parents of patient 6 were not examined), with no selection for the original IDs.

Identification of a ZNF445 truncating variant

We re-analyzed the previously obtained WES data in patients 1 and 2 and their parents, and executed WES in patients 3–6 and the parents of patients 3–5 in this study. Consequently, we revealed a nonsense variant on the last exon 8 of ZNF445 (NM_181489.6:c.2803C>T:p.(Gln935*)) in patient 1 (Fig. 1a). This variant was present in a homozygous condition in patient 1 and in a heterozygous condition in the parents (Fig. 1b and Additional file 6: Figure S1). The variant was completely absent from public and in-house databases utilized in this study and was assessed to have high pathogenicity. Consistent with the notion that a premature termination on the last exon does not cause nonsense mediated mRNA decay [8], quantitative RT-PCR for lymphoblastoid cell lines showed a similar ZNF445 expression dosage between patient 1 and control subjects (Fig. 1c), and western blot analysis revealed a truncated ZNF445 protein consistent with loss of two of 14 ZF domains in patient 1 (Fig. 1d).

While the parents had the same rare variant, PLINK analysis (https://www.cog-genomics.org/plink/1.9/) [9] argued against consanguinity between the parents (Additional file 2: Table S2). Unfortunately, we could not examine the paternal and maternal grandparents, because of their refusal to receive molecular studies.

No other rare (minor allele frequency ≤ 0.01) variant with high predicted pathogenicity (CADD-PHRED score > 20) was identified in ZNF445 of patients 2–6 and the parents of patients 2–5 as well as in other causative or candidate oocyte and zygotic factor genes for MLIDs such as NLRP2, NLRP7, KHCDC3L, NLRP5, TRIM28, PADD6, OOB, UHRF1, ZAR1, and ZFP57 [1–3, 10, 11] of patients 1–6 and the parents of patients 1–5.

Genomewide methylation analysis

Genomewide methylation analysis was performed using Infinium MethylationEPIC Kit (EPIC) (Illumina), covering > 850,000 CpGs in the genome. The selection of CpGs to be examined and the definitions of abnormally methylated CpGs and aberrantly methylated iDMRs were described in "Methods".

The methylation analysis for 855 CpGs on 78 iDMRs revealed severe hypomethylation of most CpGs at the MEG3:TSS-DMR, moderate hypomethylation of roughly two-thirds of CpGs at the H19/IGF2:IG-DMR, mild-to-moderate hypomethylation of several CpGs at the GNAS-AS1:TSS-DMR, and mild hypomethylation of a single to few CpGs at the DRA53:TSS-DMR, MEST:alt-TSS-DMR, IGF2:Ex9-DMR, and IGF2:alt-TSS-DMR, together with a mildly hypomethylated single CpG at the MEG3/DLK1:IG-DMR and a mildly hypermethylated single CpG at the MEG8:Int2-DMR in patient 1 (Fig. 2a and
The MEG3:TSS-DMR, H19/IGF2:IG-DMR, IGF2:Ex9-DMR, and GNAS-AS1:TSS-DMR were regarded as aberrantly methylated iDMRs (Fig. 2a and Additional file 3: Table S3). The hypomethylated CpGs tended to be clustered within the affected iDMRs. The parents had no aberrantly methylated CpG,
except for a single mildly hypermethylated CpG at the MEG3:TSS-DMR in the father and a single mildly hypermethylated CpG at the Clorf177-DMR in the mother.

By contrast, the methylation analysis for 333,868 autosomal CpGs at CpG islands and their north and south shores and shelves showed a comparable distribution of \( \beta \)-values indicating the methylation levels among patient 1, the parents, and control subjects, as illustrated with violin plots (Additional file 7: Figure S2). Indeed, only 24 CpGs were found to be abnormally methylated on non-iDMRs of patient 1 (Additional file 4: Table S4).

**Methylation analysis for the MEG3/DLK1:IG-DMR**

Since the MEG3/DLK1:IG-DMR was barely examined by EPIC, bisulfite sequencing was carried out for CG-A within the previously identified DMR segment named CG-6 (Fig. 2b and Additional file 8: Figure S3). As a whole, CG-A was markedly hypomethylated in patient 1 as well as in a upd(14)mat case, although a few CpGs including the single CpG examined by EPIC were less severely hypomethylated.

**Clinical report**

Detailed clinical findings of patient 1 up to 4 5/12 years have been reported previously [6]. In short, she was conceived naturally and delivered by a caesarean section because of fetal growth arrest at 34 weeks of gestation. She exhibited all the six Netchine–Harbison clinical diagnostic features for SRS: (1) small for gestational age (birth length, \(-2.9\) SD; and birth weight, \(-3.8\) SD), (2) postnatal growth failure (height at 24 months, \(-4.5\) SD); (3) relative macrocephaly at birth (occipitofrontal circumference SDS at birth, \(+2.5\) above birth length SDS and \(+3.4\) above birth weight SDS); (4) protruding forehead during 1–3 years; (5) body asymmetry; and (6) feeding difficulties requiring tube feeding [12]. She also manifested salient clinical features prompting genetic testing for Prader–Willi syndrome (PWS) before 6 years of age, such as severe hypotonia with poor suck and global developmental delay [13]. On the last examination at 5 9/12 years of age, she showed growth failure (height, \(-4.0\) SD; weight, \(-6.0\) SD; and occipitofrontal circumference, \(-1.9\) SD) despite growth hormone treatment from 3.0 years of age.

The parents were clinically healthy, with the paternal height of 164 cm (\(-1.2\) SD) and the maternal height of 150 cm (\(-1.6\) SD). Allegedly, the paternal and maternal grandparents were also healthy, and there was no consanguinity.

**Discussion**

We identified a homozygous nonsense variant of ZNF445 in patient 1. This variant was completely absent from the public and in-house databases utilized in this study and was shown to produce a truncated ZNF445 protein missing two ZF domains. Furthermore, it is notable that (1) ZNF445 is associated with a high probability of being loss-of-function intolerant score (1.0) [14], and (2) no homozygous loss-of-function variant has been registered in the gnomAD database (https://gnomad.broadinstitute.org/v2.1.1), although heterozygous loss-of-function variants have been recorded. These findings, together with the normal phenotype and the nearly complete lack of aberrant methylation pattern in the heterozygous parents of patient 1, suggest that ZNF445 has an essential biological function in the human and that biallelic rather than monoallelic variants of ZNF445 can lead to disease phenotype. Taken together, it is likely that the ZNF445 truncating variant is a disease-causing variant with a recessive effect.

Patient 1 had TS14-compatible severe hypomethylations affecting the MEG3/DLK1:IG-DMR and MEG3:TSS-DMR and mild-to-moderate MLID affecting several iDMRs, in the presence of the ZNF445 variant. In this regard, previous studies have shown that: (1) in hES cells or HEK293T cells, ZNF445 binds to multiple iDMRs including the iDMRs affected in patient 1, to maintain the postfertilization imprint [4], (2) while the postzygotic methylation imprint of most iDMRs is preserved by both ZFP57 and ZNF445 or primarily by ZFP57, that of the MEG3/DLK1:IG-DMR is maintained primarily by ZNF445 [4, 5]; and (3) the MEG3/DLK1:IG-DMR functions as a hierarchically upper regulator for the methylation pattern of the MEG3:TSS-DMR, so that the hypomethylated MEG3/DLK1:IG-DMR renders the MEG3:TSS-DMR hypomethylated [15]. These findings would explain, in terms of a defective ZNF445 function, why patient 1 had the severely hypomethylated MEG3/
DLK1:IG-DMR (CG-A) and MEG3:TSS-DMR and the mild-to-moderate degrees of MLID. This notion would be supported by the development of severe hypomethylation of the PLAGL1:alt-TSS-DMR leading to transient neonatal diabetes mellitus and MLID in patients with ZFPS7 pathogenic variants [3], because the postzygotic methylation imprint of the PLAGL1:alt-TSS-DMR is preserved primarily by ZFPS7 [4, 5].

For the MEG3/DLK1:IG-DMR, the CG-A within CG-6 was severely hypomethylated in patient 1 as well as in a upd(14)mat case. In this regard, the MEG3/DLK1:IG-DMR is known to harbor at least two DMR segments (CG-4 and CG-6) (Fig. 2B and Additional file 8: Figure S3) [15], and the previous bisulfite sequencing and pyrosequencing analyses have shown that CG4 in patient 1 is irregularly (not differentially) methylated and, consequently, associated with apparently normal methylation indices (Additional file 1: Table S1 and Fig. 2A and 2C in Kagami et al. [6]). It is possible, therefore, that CG-A contains the major target sequence such as the ICR for ZNF445 and functions as a hierarchically upper regulator for the methylation pattern of the MEG3:TSS-DMR [15]. However, both CG-A and CG-4 reside within the regions harboring ZNF445 binding sites identified by ChIP analysis using hES cells [4] (Additional file 8: Figure S3), and further studies are required to determine the precise ZNF445 binding site(s) with a biological function within the MEG3/DLK1:IG-DMR. In this context, the segment with continuously hypomethylated CpGs within the H19/IGF2:IG-DMR may harbor the major target sequence for ZNF445.

The human ZNF445 expression is strong in the oocyte and the 2–4 cell embryos and becomes weak afterwards [5]. This may suggest that the methylation defects of patient 1 primarily occurred around the time of the high ZNF445 expression. In addition, since human ZFPS7 expression remains nearly undetectable in the oocyte and the 2–8 cell embryos and becomes obvious in the inner cell mass [5], the deleterious effects of ZNF445 deficiency in the oocyte and the 2–4 cell embryos could not be compensated for by the ZFPS7 function. However, it is unlikely that the maternal ZNF445 variant in the oocyte is responsible for the development of methylation defects of patient 1. Although the MEG3/DLK1:IG-DMR, MEG3:TSS-DMR, and H19/IGF2:IG-DMR were obviously hypomethylated in patient 1, these iDMRs are methylated in the sperm, not in the oocyte [16]. By contrast, it may be possible that the homozygous ZNF445 variant at the initial postzygotic stage is relevant to the development of methylation defects in patient 1. In this regard, while the methylation disturbance occurring at such an initial stage is assumed to lead to relatively severe methylation defects at multiple loci, most of the ZNF445 bound iDMRs in HEK293T cells, such as the DIRA53:TSS-DMR, ZDBF2/GPR1:IG-DMR, MEST:alt-TSS-DMR, PEG13:TSS-DMR, KCNQ1OT1:TSS-DMR, NNAT:TSS-DMR, GNAS-NESP:TSS-DMR, GNAS-AS1:TSS-DMR, GNAS-XL:Ex1-DMR, and SNUI3:alt-TSS-DMR [5], were barely affected in patient 1. However, it has been suggested for the maternal effect gene NLRP5 that although the concepti of variant positive mothers have broad methylation defects, natural epigenetic resetting takes place during the embryonic development, leaving only a few methylation defects detectable postnatally [17]. If such an epigenetic resetting has occurred after broad methylation defects at the initial postzygotic stage in patient 1, this would lead to the development of MLID associated with severe hypomethylation of the MEG3/ DLK1:IG-DMR (CG-A), whose postzygotic methylation imprint is primarily maintained by ZNF445 [4, 5], and resultant marked hypomethylation of the MEG3:TSS-DMR [15], together with mild-to-moderate hypomethylation at several loci. Notably, the broad methylation defects at the initial postzygotic period, if it has indeed occurred in patient 1, could be due to the maternal effect of the ZNF445 variant in the fertilized ovum. Thus, the ZNF445 variant may have behaved not only as a zygotic factor leading to the methylation defects in a locus-dependent manner, but also as an oocyte factor, resulting in the initial broad methylation defects [2, 4, 5, 11].

Previous studies in patients with MLIDs have revealed no pathogenic ZNF445 variant [5], although they have identified multiple pathogenic ZFPS7 variants [3]. In this regard, ZNF445 is expressed in the oocyte and initial postzygotic stage, whereas ZFPS7 is expressed from a relatively later postzygotic stage [4, 5]. Thus, while even biallelic apparently amorphic variants of ZFPS7 have been reported [3], biallelic severe loss-of-function variants of ZNF445 may cause embryonic lethality, because of the disrupted methylation maintenance from a very early developmental stage. Thus, the truncating variant in patient 1 would be a hypomorphic rather than amorphic variant. One may argue against the lethality of ZNF445 biallelic amorphic variants, because mice carrying either zygotic or maternal-zygotic Znf445 deletions have no discernible methylation defects in the brain at 12.5 embryonic days, and one-third of such mice survive to adulthood [4]. However, in contrast to human ZNF445 and ZFPS7 expression patterns, mouse Znf445 and Zfp57 are continuously expressed from the zygote to early blastocyst stage, with the expression level being higher in Zfp57 than in Znf445 [4]. It is likely, therefore, that the deleterious effects of Znf445 deficiency could be compensated for by the high Zfp57 expression in the mouse [4]. In support of the compensatory effects between Zfp57
and Znf445, the Zfp57 and Znf445 double knockout mice have massive methylation defects and nearly lethal in the embryonic life [4]. Furthermore, previous studies in search of a ZNF445 variant(s) have been performed for MLID-positive patients diagnosed with transient neonatal diabetes mellitus (n = 3), BWS (n = 28), and PHP-Ib (n = 10) [5]. Considering the critical role of ZNF445 in the methylation maintenance of the MEG3/DLK1:IG-DMR, ZNF445 variants may be hidden in patients with TS14 caused by epimutations. Consistent with this, a ZNF445 variant was not identified in patients 2–6 with IDs other than TS14. Thus, we are planning to perform ZNF445 analysis and methylation profiling in patients with TS14 caused by epimutations.

Several matters should be pointed out in this study. First, patient 1 was diagnosed with TS14, because of the marked hypomethylation of the MEG3/DLK1:IG-DMR and MEG3:TSS-DMR. Indeed, the coexistence of SRS- and PWS-compatible phenotypes is characteristic of TS14 in infancy to early childhood and is observed in ~ half of TS14 patients at that period [18]. Furthermore, it is likely that the moderately hypomethylated H19/IGF2:IG-DMR has also contributed to the development of typical SRS phenotype in patient 1 [12], as have been implicated previously [6]. Second, no pathogenic variant was identified in the MLID-related oocyte and zygotic factor genes of patients 2–6 and the parents of patients 2–5. This may imply a relatively small relevance of genetic variants to MLIDs, while it is possible that a pathogenic variant(s) is hidden in noncoding regions and that several genes for MLIDs remain undetected at present. Third, the parents were heterozygotes for the extremely rare ZNF445 variant. Thus, although the PLINK analysis argued against consanguinity, they might be very distant relatives. Fourth, the degree of hypomethylation was more obvious for most of the abnormally methylated CpGs in the EPIC analysis than in than HumanMethylation450 BeadChip utilized in the previous study (Fig. 2B in Kagami et al. [6]), although the overall methylation pattern was similar between the two methods. This would primarily be due to the difference in the DNA samples of patient 1 (obtained at 3 years of age in the previous study and at 5 years of age in this study) and in the control subjects employed in the two methods. Fifth, the single CpG at the MEG8:Int2-DMR was hypermethylated. This is consistent with the previous finding that this DMR shows a methylation pattern opposite to that of the MEG3:TSS-DMR and MEG3/DLK1:IG-DMR [19]. Lastly, the distribution of the β-values for autosomal CpGs at and around CpG islands was comparable among patient 1, the parents, and control subjects. This would imply that ZNF445 mainly, if not exclusively, functions at ICRs within iDMRs.

Conclusions
We identified for the first time a homozygous variant of ZNF445 in a patient with TS14 and MLID. Further studies will permit to clarify the role of ZNF445 variants in the development of MLIDs.

Methods
Samples and primers
Molecular studies were performed for leukocyte genomic DNA (gDNA) samples. Primers utilized are shown in Additional file 5: Table S5.

Whole exome sequencing (WES)
In patients 1 and 2, we searched for a variant(s) of ZNF445 and other recently reported MLID-related genes, using the previously obtained WES data [6, 7]. In patients 3–6 and the parents of patients 3–5, we performed WES in this study. In brief, WES was carried out using SureSelect Human All Exon V6 (Agilent Technologies), and captured libraries were sequenced by NextSeq 500 (Illumina) with 150-bp paired-end reads. Exome data processing, variant calling, and variant annotation were carried out, as described previously [20]. Human GRCh37/h19 (https://genome.ucsc.edu) was utilized as the reference genome, and NM_181489.6 (https://www.ncbi.nlm.nih.gov/genbank) as the reference for a ZNF445 variant.

We extracted rare variants with minor allele frequencies of ≤0.01 in all the following public databases and in-house database (n = 218): (1) Whole genome and exome data for East Asian Population in Genome Aggregation Database (gnomAD_genome_EAS & gnomAD_exome_EAS) (http://gnomad.broadinstitute.org/); (2) Human Genetic Variation Database (HGVD) (http://www.hgvd.genome.med.kyoto-u.ac.jp/); and (3) whole genome sequences of 8380 healthy Japanese individuals and construction of the highly accurate Japanese population reference panel (8.3KJPN) (https://igvd.megabank.tohoku.ac.jp/). Final variants were annotated with Annovar [21].

In silico pathogenicity predictions were carried out for identified rare variants, using the following methods: (1) CADD (Combined Annotation–Dependent Depletion) (http://cadd.gs.washington.edu/); (2) PP2_HVAR (Polyphen-2 Hum Var) (http://genetics.bwh.harvard.edu/pph2/); (3) SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org/); and (4) MutationTaster (http://www.mutationtaster.org/).

Exome sequencing data were also utilized to examine an exonic deletion(s) by exome sequencing-based CNV calling [22] and consanguinity by PLINK [9].
Western Blotting
We introduced human ZNF445 cDNA, wildtype or p.Gln935* created by mutagenesis, into pcDNA3 vector with 3xFLAG-tag using the Gibson assembly technique (New England Biolabs, Ipswich, MA, USA). The vectors were transfected into HEK293 cells using Lipofectamine 3000 (ThermoFisher Scientific), and cell lysates were prepared from transfected cells maintained for 48 h. Western blotting was performed with anti-FLAG M2 antibody (Sigma-Aldrich) and anti-tubulin antibody (Abcam) as primary antibodies and with anti-Mouse IgG and anti-Rat IgG (Sigma-Aldrich) as secondary antibodies.

Genomewide methylation analysis
Genomewide methylation analysis was performed, using Infinium MethylationEPIC Kit (EPIC) (Illumina) covering > 850,000 CpGs in the genome. In brief, 500 ng of bisulfite-treated gDNA was subjected to the beadchip and was scanned using the Illumina iScan system. Then, we applied background subtraction and, subsequently, discarded CpGs with the detection P values of > 0.01 and/or no signal intensities, as well as those on the sex chromosomes. Data import, quality control, and correction of multiple batch effect among arrays were performed by R version 3.4.1 using ChAMP R package (version 2.8.9).

We obtained β-values indicating the methylation levels for 855 CpGs on 78 iDMRs, after excluding CpGs showing age-related drift and sex bias [23–26]. We calculated the mean and SD of β-value at each CpG in 24 control subjects and obtained the difference between the β-value of each case (patient 1, the father, and the mother) and the mean β-value of the control group (Δβ). The methylation level of each CpG (probe) was interpreted as abnormal, when the |β| > 3 SD of the mean in controls and |Δβ| > 0.05. When at least two consecutive probes with abnormally methylated levels were detected within iDMRs harboring at least four examined probes, such iDMRs were defined as aberrantly methylated iDMR [27].

We further obtained β-values indicating the methylation levels for 333,868 autosomal CpGs at CpG islands based on the UCSC criteria and their north and south shores and shelves, and drew violin plots using the data. To identify abnormally methylated CpGs on non-iDMRs, we took the following steps: (1) exclusion of CpGs in which the values for the mean + 3 SD were above 1.0 or those for the mean − 3 SD were below 0; (2) extraction of CpGs with the |β| > 3 SD of the mean in controls and |Δβ| > 0.05; (3) exclusion of CpGs on the iDMR; and (4) exclusion of CpGs showing age-related drift and sex bias [23–26].

Other experiments
Other experiments were carried out by the standard methods.

Abbreviations
iDMR: Imprinting-associated DMR; MLID: Multilocus imprinting disturbance; ID: Imprinting disease; ZF: Zinc finger; ICR: Imprinting control region; KAP1: KRAB-associated protein 1; CHIP: Chromatin immunoprecipitation; hES: Human embryonic stem; HEK293T: Human embryonic kidney 293 T, T514: Temple syndrome, BWS: Beckwith–Wiedemann syndrome; PHP-Ib: Pseudohypoparathyroidism type Ib; SRS: Silver–Russell syndrome; WES: Whole exome sequencing; EPIC: Infinium MethylationEPIC Kit; PWS: Prader–Willi syndrome.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01106-5.

Acknowledgements
We are grateful to the patients and their parents for their cooperation. We thank Drs. Keisuke Nagasaki, Tomonobu Hasegawa, Yasuyuki Fukuhara, and Yuko Akutsu for providing us with clinical data and materials for molecular studies. We also thank Drs. Sayaka Kawashima, Takahiro Inoue, Shinichiro Sano, Kanako Tanase-Nakao, Ms. Fumiko Kato, Saori Miyasako, Tamae Tanji, and Aki Ueda for their support in molecular analyses.

Authors’ contributions
MK designed the study with input from TO. MK, K H-I, KM, KN, SN, MK, HS and ST performed molecular studies. YO and TO obtained clinical data and blood samples. MK and TO wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by Grants from the Japan Society for the Promotion of Science (JSPS) (18K06336), the National Center for Health and Development (2019B-4), the Japan Agency for Medical Research and Development (AMED) (JP20ek0109373 and JP21ek0109549), and Takeda Science Foundation.

Availability of data and materials
All data generated or analyzed during this study are available from the corresponding author on reasonable request.
Declarations

Ethical approval
This study was approved by the Ethics Committee at National Center for Child Health and Development, and was performed after obtaining written informed consent.

Consent for publication
We obtained written permission to publish clinical and molecular data from the parents of patients 1–6.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
2. Department of Maternal Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
3. Department of Pediatrics, Shizuoka Saiseikai Hospital, Oshika 1-1-1, Suruga-ku, Shizuoka 422-8527, Japan.
4. Department of Biochemistry, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
5. Department of Systems Biomedicine, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
6. Department of Pediatrics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
7. Department of Pediatrics, Hamamatsu Medical Center, Tomitsuka 328, Naka-ku, Hamamatsu 432-8580, Japan.

Received: 24 March 2021   Accepted: 18 May 2021

Published online: 26 May 2021

References
1. Mackay DJ, Eggermann T, Buiting K, Garin I, Linglart A, et al. Multilocus methylation defects in imprinting disorders. Biomol Concepts. 2015;6:47–57.
2. Begemann M, Rezwan FI, Beygo J, Docherty JL, Marks SM, White HE, Acerini CL, et al. Maternal variants in NLPR and other maternal effect proteins are associated with multilocus imprinting disturbance in offspring. J Med Genet. 2018;55:497–504.
3. Mackay DJ, Callaway JL, Marks SM, White HE, Acrerini CL, Boonen SE, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFPS7. Nat Genet. 2008;40:949–51.
4. Takahashi N, Coluccio A, ThorhALL CW, Planet E, Shi H, Offer S, et al. ZNF445 is a primary regulator of genomic imprinting. Genes Dev. 2019;33:49–54.
5. Monteagudo-Sánchez A, Hernandez Mora JR, Simon C, Burton A, Tenorio J, Lapunzina P, et al. The role of ZFPS7 and additional KRAB-zinc-finger proteins in the maintenance of human imprinting methylation and multilocus imprinting disturbances. Nucleic Acids Res. 2020;48:11394–407.
6. Kagami M, Yanagisawa A, Ota M, Matsuura K, Nakamura A, Matsubara K, et al. Temple syndrome in a patient with variably methylated CpGs at the primary MEG3:DMR and the MEG3:DMR at human chromosome 14q32.2. Clin Epigenet. 2020;12:139.
7. Sano S, Matsuura K, Nakabayashi K, Hara K, et al. Beckwith-Wiedemann syndrome and pseudohyoparathyroidism type IIb in a patient with multilocus imprinting disturbance: a female-dominant phenomenon? J Hum Genet. 2016;61:765–9.
8. Kuzmiak HA, Macquat LE. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med. 2006;12:306–10.
9. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.
10. Cubells MV, Pinolata L, Verma A, Sparago A, Pette RD, Montecilli M, et al. Loss-of-function maternal-effect mutations of PAD16 are associated with familial and sporadic Beckwith-Wiedemann syndrome with multi-locus imprinting disturbance. Clin Epigenet. 2020;12:139.
11. Monk D, Mackay D, Eggermann T, Maher ER, Riccio A. Genomic imprinting disorders: lessons on how genome, epigenome and environment interact. Nat Rev Genet. 2019;20:235–48.
12. Wakeling EL, Brioude F, Lokulo-Sodipe O, O’Connell SM, Salem J, Blek J, et al. Diagnosis and management of Silver-Russell syndrome: First inter‑national consensus statement. Nat Rev Endocrinol. 2017;13:105–24.
13. Gunay-Aygun M, Schwartz S, Heeger S, ORiordon MA, Cassidy SB. The changing purpose of Prader-Willi syndrome: clinical diagnostic criteria and proposed revised criteria. Pediatrics. 2001;108:E92.
14. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.
15. Kagami M, OSullivan MJ, Green AJ, Watanabe Y, Arisaka O, Masawa N, et al. The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet. 2016;10:e1004992.
16. Okae H, Chiba H, Hiura H, Hamada H, Sato A, Utsunomiya T, et al. Genome-wide analysis of DNA methylation dynamics during early human development. PLoS Genet. 2014;10:e1004868.
17. Docherty LE, Rezwan FI, Poole RL, Turner CL, Kivuva E, Maher ER, et al. Mutations in NLR5 are associated with reproductive wastage and multi-locus imprinting disorders in humans. Nat Commun. 2015;6:8086.
18. Kagami M, Nagasaki K, Kosaki R, Horikawa R, Naiki Y, Saihiti S, et al. Temple syndrome: comprehensive molecular and clinical findings in 32 Japanese patients. Genet Med. 2017;19:1356–66.
19. Ben S, Kolarova J, Gillessen-Kaesbach G, Buiting K, Beygo J, Caliebe A, et al. The differentially methylated region of MEG8 is hypermethylated in patients with Temple syndrome. Epigenomics. 2015;7;1089–97.
20. Miyado M, Fukami M, Takada S, Terao M, Nakabayashi K, Hata K, et al. Germline-derived gain-of-function variants of Gs-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2019;30:877–89.
21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
22. Nord AS, Lee M, King MC, Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genom. 2011;12:184.
23. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115.
24. Hannum G, Guinney J, Zhao L, Yang X, Zhang L, Lau J, et al. Genome-wide DNA methylation profiler reveals quantitative views of human aging rates. Mol Cell. 2013;49:359–67.
25. Alisch RS, Barwick BG, Chopra P, Myrick LK, Satten GA, Conney KN, et al. Age-associated DNA methylation in pediatric populations. Genome Res. 2012;22:623–32.
26. Chen Y, Lemire M, Choufani S, Butcher D, Grafodatskaya D, Zanke BW, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013:8:203–9.
27. Docherty LE, Rezwan FI, Poole RL, Jagoe H, Lake H, Lockett GA, et al. Genome-wide DNA methylation analysis of patients with imprinting disorders identifies differentially methylated regions associated with novel candidate imprinting genes. J Med Genet. 2014;51:229–38.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.